Akums Drugs and Pharmaceuticals logo

Akums Drugs and Pharmaceuticals financials: balance sheet, profit and loss, cash flow

NSE: AKUMSBSE: 544222Pharmaceuticals & BiotechnologySmall Cap

Akums Drugs and Pharmaceuticals Limited · Face value ₹2 · Listed Aug 2024 · Issue price ₹679
Last close ₹741.05up ₹18.35 (2.54%)BSE ₹741.10

Share price at the NSE close on 29 Oct 2026. Previous close ₹722.70.

29 Oct: open ₹717.60, high ₹745.00, low ₹714.85

52-week range of traded prices to 29 Oct 2026
₹409.30Low, 21 Jan 2026₹838.80High, 23 Sep 2026
Market cap
₹11,664 Cr630th largest listed
P/E
39.98
P/B
3.52
Dividend yield
0.40%
ROE
9.2%
ROCE
12.0%
Debt to equity
0.02
Volume, NSE
1,10,47256.9% delivered

Akums Drugs and Pharmaceuticals' financial statements for the 2 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them.

2 years at a glance

₹ crore, years to March.Akums Drugs and Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
4,11834414Mar 254,35925673Mar 26
Peak revenue ₹4,359 Cr, year to Mar 2026; lowest ₹4,118 Cr, year to Mar 2025

Operating and net margin, per cent

  • Operating margin
  • Net margin
12.0%5.9%11.3%12.0%8.3%5.9%Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue4,359
  2. Materials and goods−2,514
  3. Employee costs−754
  4. Other expenses−570
  5. Operating profit522
  6. Depreciation−155
  7. Other income+129
  8. One-off items−20
  9. Finance costs−94
  10. Profit before tax382
  11. Tax−126
  12. Net profit256

What the company owns

  • Plant, investments and other assets₹2,214 Cr
  • Cash and bank₹1,681 Cr
  • Receivables₹797 Cr
  • Inventory₹756 Cr

What pays for it: net worth and liabilities

  • Net worth₹3,331 Cr
  • Other liabilities₹1,441 Cr
  • Owed to suppliers₹602 Cr
  • Borrowings₹73 Cr

Akums Drugs and Pharmaceuticals business segments, year to Mar 2026

A reportable segment is a line of business the company must report on its own. Consolidated, ₹ crore, as the company reports them. A segment at a loss has no share of profit.Akums Drugs and Pharmaceuticals segment results by quarter

Revenue by segment

₹4,359 CrTotal
  • CDMO₹3,485 Cr80.0% of total
  • Domestic Branded Formulations₹446 Cr10.2% of total
  • API₹184 Cr4.2% of total
  • International Branded Formulations₹143 Cr3.3% of total
  • Trade Generics₹100 Cr2.3% of total

Profit by segment

  • CDMO₹329 Cr73.0% of total
  • Domestic Branded Formulations₹87 Cr19.4% of total
  • International Branded Formulations₹34 Cr7.6% of total

Segment results by year

Consolidated, ₹ crore, years to March.

  • CDMO

    Revenue, ₹ crore
    Profit, ₹ crore
  • Domestic Branded Formulations

    Revenue, ₹ crore
    Profit, ₹ crore
  • API

    Revenue, ₹ crore
    Profit, ₹ crore
  • International Branded Formulations

    Revenue, ₹ crore
    Profit, ₹ crore
  • Trade Generics

    Revenue, ₹ crore
    Profit, ₹ crore
₹ croreMar 2025Mar 2026
Revenue of all businesses4,1184,359
Company revenue, as in its results4,1184,359
Revenue3,2083,485
Revenue growth–8.6%
Profit332329
Profit growth–−1.0%
Margin10.4%9.4%
Return on capital16.8%26.6%
Assets2,7023,054
Liabilities7281,818
Capital employed1,9741,237
Revenue434446
Revenue219184
Revenue143143
Revenue115100
00
Profit is before tax and finance costs, the way companies report their segments.

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Akums Drugs and Pharmaceuticals quarterly results

₹ croreMar 2025Mar 2026Filed 14 MayJun 2026Twelve monthsFiled 8 Aug
Revenue from operations4,1184,3594,502
3,6543,8373,934
Materials and goods bought2,4332,5142,577
Employee costs716754779
Other expenses504570578
Operating profit before depreciation464522568
Operating margin11.3%12.0%12.6%
Materials, % of revenue59.1%57.7%57.2%
Employee costs, % of revenue17.4%17.3%17.3%
Other expenses, % of revenue12.2%13.1%12.8%
Depreciation and amortisation153155159
Operating profit after depreciation311367409
Other income52129132
Finance costs359496
Profit before one-off items and tax329402446
One-off items17−20−20
Profit before tax345382426
1126133
344256293
Other comprehensive income−112
Total comprehensive income343257295
Net margin8.3%5.9%6.5%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2025Mar 2026Filed 14 May
3,0643,331
3,0473,313
Share capital3131
Reserves3,0163,283
Belonging to outside owners of subsidiaries1718
Borrowings1473
8941,095
1561,021
Total assets4,1135,447
1,8391,887
2,2753,560
Net debt−563−1,608
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2025Mar 2026Filed 14 May
4651,181
660450
149−177
Receivables34−56
Inventories−51−75
Payables119−27
Other working capital47−20
Tax paid−83−87
Capital spending272231
Free cash flow193951
−548−930
7334
Dividends paid00
Shares bought back00
Shares issued6370
Net change in cash−10285
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.Akums Drugs and Pharmaceuticals dividend history

₹ per shareMar 2025Mar 2026Filed 14 May
Earnings per share₹22.60₹16.67
Diluted earnings per share₹22.60₹16.67
Dividend per share–₹3.00
Book value per share₹193.59₹216.41
Dividend payout–18.0%
Shareholder yield−8.6%0.0%
Market cap at the year end (₹ crore)7,4487,336
RatioMar 2025Mar 2026Filed 14 May
Revenue growth–5.8%
Operating profit growth–12.4%
Net profit growth–−25.4%
Earnings per share growth–−26.2%
11.1%8.0%
–−3.1 pts
From the net margin–−3.2 pts
From asset turnover–−0.7 pts
From borrowing–0.8 pts
Return on capital employed10.1%10.8%
Cash conversion135.3%460.7%
Interest cover9.03.9
Debt to equity0.000.02
Receivable days6867
Inventory days102110
Payable days9687
Cash conversion cycle, days7489
Working capital days7372
Asset turnover1.000.91
Assets per rupee of net worth1.351.50
Sales per rupee of plant2.963.01
Capital spending to depreciation1.771.49
Plant being built, % of plant in use11.5%12.2%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
5.3%
Cash from operations against operating profit
226.3%
Measure3 years
Return on equity, average9.6%
Return on capital employed, average10.5%
Operating margin, average11.6%
Net margin, average7.1%
Asset turnover, average0.96
Cash conversion cycle, days, average81
Interest cover, average6.4
Debt to equity, average0.01

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations1,181
Cash from investing−930
Cash from financing34
Capital spending231
Dividends paid0
Shares bought back0
Shares issued for cash0
Borrowings raised59
Borrowings repaid0

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2025Mar 2026
Altman Z-scorePublished threshold 1.816.994.50
Beneish M-scorePublished threshold −1.78–−3.36
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–0.11
Receivables growth less revenue growthOur threshold 0 percentage points–−2.44
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–7.69
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–1.84
Assets under construction, years of additionsOur threshold 2 years of additions–0.83
Effective tax ratePublished threshold 17.16 per cent0.4332.90
Tax charged less tax paid, % of profitOur threshold 10 percentage points−23.6610.03
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
10 Apr 2026ICRA LimitedFund-based/Non-fund based-Others[ICRA]AA /[ICRA]A1+Review, Re-affirmStable85
10 Apr 2026ICRA LimitedCommercial Paper[ICRA]A1+New, New200
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.